Marie Thibault
Stock Analyst at BTIG
(3.45)
# 1,141
Out of 5,182 analysts
122
Total ratings
44.07%
Success rate
5.87%
Average return
Main Sectors:
Stocks Rated by Marie Thibault
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Reiterates: Buy | $131 | $96.81 | +35.32% | 17 | Apr 17, 2026 | |
| KMTS Kestra Medical Technologies | Reiterates: Buy | $32 | $22.81 | +40.29% | 4 | Apr 7, 2026 | |
| MMED MiniMed Group | Initiates: Buy | $25 | $14.44 | +73.13% | 1 | Mar 31, 2026 | |
| DXCM DexCom | Reiterates: Buy | $85 | $63.98 | +32.85% | 11 | Mar 9, 2026 | |
| DCTH Delcath Systems | Maintains: Buy | $23 → $19 | $10.86 | +74.95% | 5 | Feb 26, 2026 | |
| PODD Insulet | Reiterates: Buy | $380 | $203.73 | +86.52% | 7 | Feb 18, 2026 | |
| MASI Masimo | Downgrades: Neutral | n/a | $178.39 | - | 8 | Feb 18, 2026 | |
| ATRC AtriCure | Reiterates: Buy | $54 | $29.72 | +81.70% | 8 | Feb 18, 2026 | |
| OM Outset Medical | Maintains: Buy | $17 → $15 | $4.61 | +225.38% | 3 | Feb 12, 2026 | |
| EW Edwards Lifesciences | Reiterates: Buy | $103 | $80.99 | +27.18% | 3 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $110 | $64.23 | +71.26% | 16 | Feb 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $9.78 | +155.62% | 4 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $88 | $61.62 | +42.81% | 5 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $2 | $0.44 | +352.80% | 3 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $21.19 | +41.58% | 2 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $215 | $125.32 | +71.56% | 8 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.58 | - | 2 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $62 → $65 | $67.08 | -3.10% | 8 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.54 | - | 2 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.42 | - | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.77 | - | 1 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $6 | $503.63 | -98.81% | 1 | Apr 9, 2020 |
Abbott Laboratories
Apr 17, 2026
Reiterates: Buy
Price Target: $131
Current: $96.81
Upside: +35.32%
Kestra Medical Technologies
Apr 7, 2026
Reiterates: Buy
Price Target: $32
Current: $22.81
Upside: +40.29%
MiniMed Group
Mar 31, 2026
Initiates: Buy
Price Target: $25
Current: $14.44
Upside: +73.13%
DexCom
Mar 9, 2026
Reiterates: Buy
Price Target: $85
Current: $63.98
Upside: +32.85%
Delcath Systems
Feb 26, 2026
Maintains: Buy
Price Target: $23 → $19
Current: $10.86
Upside: +74.95%
Insulet
Feb 18, 2026
Reiterates: Buy
Price Target: $380
Current: $203.73
Upside: +86.52%
Masimo
Feb 18, 2026
Downgrades: Neutral
Price Target: n/a
Current: $178.39
Upside: -
AtriCure
Feb 18, 2026
Reiterates: Buy
Price Target: $54
Current: $29.72
Upside: +81.70%
Outset Medical
Feb 12, 2026
Maintains: Buy
Price Target: $17 → $15
Current: $4.61
Upside: +225.38%
Edwards Lifesciences
Feb 11, 2026
Reiterates: Buy
Price Target: $103
Current: $80.99
Upside: +27.18%
Feb 9, 2026
Reiterates: Buy
Price Target: $110
Current: $64.23
Upside: +71.26%
Feb 6, 2026
Reiterates: Buy
Price Target: $25
Current: $9.78
Upside: +155.62%
Feb 6, 2026
Reiterates: Buy
Price Target: $88
Current: $61.62
Upside: +42.81%
Feb 5, 2026
Maintains: Buy
Price Target: $4 → $2
Current: $0.44
Upside: +352.80%
Jan 28, 2026
Reiterates: Buy
Price Target: $30
Current: $21.19
Upside: +41.58%
Oct 31, 2025
Maintains: Buy
Price Target: $195 → $215
Current: $125.32
Upside: +71.56%
Aug 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.58
Upside: -
Oct 14, 2024
Maintains: Buy
Price Target: $62 → $65
Current: $67.08
Upside: -3.10%
Jun 25, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.54
Upside: -
Oct 13, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.42
Upside: -
Jan 21, 2021
Downgrades: Neutral
Price Target: n/a
Current: $6.77
Upside: -
Apr 9, 2020
Maintains: Buy
Price Target: $11 → $6
Current: $503.63
Upside: -98.81%